CN-121995057-A - Application of CXC chemokine ligand 13 as vascular calcification diagnostic marker

Abstract

The invention provides an application of CXC chemokine ligand 13 as a vascular calcification diagnostic marker, belonging to the technical field of medicines. The CXCL13 expression is high to indicate that the vascular calcification risk is high, and the reagent for detecting the CXC chemokine ligand 13 expression level can be used for preparing vascular calcification early warning reagents or early warning kits. The invention researches the action and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating vascular calcification, provides early intervention targets of vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification.

Inventors

• MENG SHU
• WANG YUEPENG
• WU YUANHAO
• LU JINGLI

Assignees

• 上海交通大学医学院附属新华医院

Dates

Publication Date

20260508

Application Date

20241106

Claims (6)

1. Use of cxc chemokine ligand 13 as a diagnostic marker for vascular calcification.
2. 2. The application of a reagent for detecting CXC chemokine ligand 13 expression level in the preparation of vascular calcification early warning reagent or early warning kit.
3. 3. The use of a reagent for detecting the expression level of CXC chemokine ligand 13 according to claim 2, in the preparation of a vascular calcification early warning reagent or an early warning kit, wherein said early warning reagent comprises a reagent for detecting the level of CXC chemokine ligand 13 in a biological sample.
4. 4. The use of a reagent for detecting the expression level of CXC chemokine ligand 13 according to claim 2, in the preparation of a vascular calcification warning reagent or warning kit, wherein said warning kit comprises a reagent for detecting the level of CXC chemokine ligand 13 in a biological sample.
5. 5. Use of a reagent for detecting the expression level of CXC chemokine ligand 13 according to claim 3 or 4, for the preparation of a vascular calcification warning reagent or warning kit, wherein said biological sample is obtained from the blood of a subject.
6. Use of CXC chemokine ligand 13 in the preparation of a medicament for the treatment of vascular calcification, wherein said medicament blocks the expression of CXC chemokine ligand 13 specific receptor CXCR 5.

Description

Application of CXC chemokine ligand 13 as vascular calcification diagnostic marker Technical Field The invention relates to the technical field of medicines, in particular to application of CXC chemokine ligand 13 as a vascular calcification diagnosis marker. Background Vascular calcification (vascular calcification, VC) is one of the most common lesions of cardiovascular disease. VC is mainly composed of three categories, atherosclerotic plaque calcification, M ǒ nckeberg medium membrane calcification and initial calcification. Each type of VC has characteristics and shares a common feature, i.e., the occurrence of VC is similar to the process of bone development, and is a regulatable pathological process, and Vascular Smooth Muscle Cells (VSMCs) play a critical role in the pathological process of VC. However, the pathological mechanism involved in vascular calcification is complex, and the molecular regulation network and key nodes of the core in the pathological process are still unclear, so that basic research is needed to solve. Therefore, the pathogenesis of vascular calcification is studied deeply, and the method has important significance for preventing and treating cardiovascular and cerebrovascular diseases. CXC chemokine ligand 13 (CXCL 13) is a chemokine of molecular mass 10.7KD and comprising 87 amino acids, which was first identified on B Lymphocytes (BLC) and attractive B lymphocytes 1 (BCA-1), belonging to the CXC chemokine superfamily. The cognate chemokines attract B lymphocytes, and act on macrophages and T cells simultaneously. CXCL13 chemokines are distributed nearly 50% in the liver, others in serum, lymph nodes and stomach, regulating B lymphocytes through attachment to their sole membrane protein receptor CXCR 5. Studies have shown that CXCL 13-CXCR 5 plays a decisive role in regulating B lymphocyte selective recruitment to sites of inflammatory injury, such as atherosclerotic plaques, outside lymphoid organs CXCL 13-CXCR 5 also plays an important role in regulating tumor microenvironment formation and tumor growth, progression and metastasis, liver injury, macrophage recruitment, induction of peri-operative neurocognitive impairment, adipocyte inflammation and lipodystrophy, and in addition, reduced CXCL13 expression is also associated with reduced osteoclast differentiation. However, the relationship between CXCL13 and vascular calcification is currently unknown. Disclosure of Invention The purpose of the present invention is to provide an application of CXC chemokine ligand 13 as a vascular calcification diagnostic marker, wherein high CXCL13 expression indicates high vascular calcification risk. To achieve the above object, the present invention provides the use of CXC chemokine ligand 13 as a diagnostic marker for vascular calcification. The invention also provides application of the reagent for detecting CXC chemokine ligand 13 expression level in preparation of vascular calcification early warning reagent or early warning kit. As a preferred embodiment, the pre-warning reagent comprises a reagent for detecting the amount of CXC chemokine ligand 13 in a biological sample. As a preferred embodiment, the early warning kit comprises reagents for detecting the level of CXC chemokine ligand 13 in a biological sample. In a preferred embodiment of the invention, the CXCL13 level in the serum of a patient is detected using an ELISA assay, and a kit for detecting CXCL13 level can also be used to detect CXCL13 level in serum. As a preferred embodiment, the biological sample is obtained from blood of a subject. The invention also provides the use of CXC chemokine ligand 13 in the manufacture of a medicament for the treatment of vascular calcification which blocks the expression of CXC chemokine ligand 13 specific receptor CXCR 5. In a preferred embodiment of the invention, CXC 5 receptor blockers are used to inhibit smooth muscle cell calcification induced by CXC chemokine ligand 13. In a preferred embodiment of the invention, transfected ADV-CXCR5-siRNA knockdown CXCL13 specific receptor CXCR5 expression in smooth muscle cells, reduces cellular calcification deposition, improves smooth muscle cell calcification under macrophage induction. The invention has the advantages that the invention researches the effect and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating vascular calcification, provides early intervention targets of vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification. Drawings FIGS. 1a-c ApoE-/-mice were fed high phosphorus, high calcium, high fat for 12 weeks, resulting in aortic calcification in mice, and aortic tissue was taken for single cell sequencing (scRNA-seq) detection to obtain 7 cell subsets. FIGS. 2a-c, wherein macrophages were reclustered into 25 subsets. Fig. 3, clusters 4, 8, 12 highly expressed resident macrophage markers Lyve, timd, folr2, defined as resident